3-甲基苯基丙酮 | 18826-61-4

• 物质功能分类: 香精与香料 - 合成香料 - 酮类香料
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 3-甲基苯基丙酮
• 中文别名: (m-甲苯基)丙酮；间甲基苯基丙酮
• 英文名称: 3-methylphenylacetone
• 英文别名: 1-(3-methylphenyl)-2-propanone；1-(m-tolyl)propan-2-one；1-(3-methylphenyl)propan-2-one；m-tolylacetone；(m-methylphenyl)acetone
• CAS: 18826-61-4
• 化学式: C₁₀H₁₂O
• 分子量: 148.205
• InChiKey: OWZZXUNOENOULT-UHFFFAOYSA-N

物化性质

• 沸点：
  228.81°C (rough estimate)
• 密度：
  0.9332 (rough estimate)
• 稳定性/保质期：
  存在于主流烟气中。

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  1

安全信息

• 危险品标志：
  Xn
• 安全说明：
  S24/25
• 危险类别码：
  R22
• 海关编码：
  2914399090
• 储存条件：
  Refrigerator (储藏温度：+4°C)

SDS

Name:	3-Methylphenylacetone 99% Material Safety Data Sheet
Synonym:	None Known
CAS:	18826-61-4

Section 1 - Chemical Product MSDS Name:3-Methylphenylacetone 99% Material Safety Data Sheet
Synonym:None Known

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
18826-61-4	3-Methylphenylacetone	99%	unlisted

Hazard Symbols: None Listed.
Risk Phrases: None Listed.

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
The toxicological properties of this material have not been fully investigated.
Potential Health Effects
Eye:
May cause eye irritation.
Skin:
May cause skin irritation. May be harmful if absorbed through the skin.
Ingestion:
May cause irritation of the digestive tract. The toxicological properties of this substance have not been fully investigated. May be harmful if swallowed.
Inhalation:
May cause respiratory tract irritation. The toxicological properties of this substance have not been fully investigated. May be harmful if inhaled.
Chronic:
No information found.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
If swallowed, do not induce vomiting unless directed to do so by medical personnel. Never give anything by mouth to an unconscious person. Get medical aid.
Inhalation:
If inhaled, remove to fresh air. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion. Vapors may be heavier than air. They can spread along the ground and collect in low or confined areas. Runoff from fire control or dilution water may cause pollution.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Absorb spill with inert material (e.g. vermiculite, sand or earth), then place in suitable container. Avoid runoff into storm sewers and ditches which lead to waterways. Clean up spills immediately, observing precautions in the Protective Equipment section. Provide ventilation.

---

Section 7 - HANDLING and STORAGE
Handling:
Wash thoroughly after handling. Use with adequate ventilation. Avoid breathing dust, vapor, mist, or gas. Avoid contact with eyes, skin, and clothing. Keep container tightly closed. Avoid ingestion and inhalation.
Storage:
Store in a tightly closed container. Store in a dry area. Keep refrigerated. (Store below 4C/39F.)

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 18826-61-4: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Clear liquid
Color: yellow
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: Not available.
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C10H12O
Molecular Weight: 148.21

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not currently available.
Conditions to Avoid:
None reported.
Incompatibilities with Other Materials:
Strong oxidizing agents.
Hazardous Decomposition Products:
Carbon monoxide, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 18826-61-4 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
3-Methylphenylacetone - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Not regulated as a hazardous material.
IMO
Not regulated as a hazardous material.
RID/ADR
Not regulated as a hazardous material.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: Not available.
Risk Phrases:
Safety Phrases:
S 24/25 Avoid contact with skin and eyes.
WGK (Water Danger/Protection)
CAS# 18826-61-4: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 18826-61-4 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 18826-61-4 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  3-甲基苯基丙酮 在 aluminum (III) chloride 、 sodium nitrite 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 8.0h， 以96%的产率得到间甲基苯腈
  参考文献：
  名称：

  无过渡金属的无应变C（sp 3）–C（sp 2）键的无酰化解离：从酮和醛到氰基和脂肪族腈的无氰化物访问

  摘要：

  首先描述了一种无过渡金属的脱酰基C（sp 3）–C（sp 2）键裂解的方法，该方法用于合成和实际的酮和醛氧化胺化成腈，使用廉价且商业上充裕的NaNO 2作为氧化剂和氮源。可以从酮和醛中以高收率平稳地获得各种带有芳基，杂芳基，烷基和烯基的腈，避免了剧毒的氰化物或过渡金属。

  DOI：

  10.1021/acs.orglett.5b03367
• 作为产物：
  描述：

  3-烯丙基甲苯 在 iron(III) chloride 、 palladium(II) trifluoroacetate 、 sodium 2,2,2-trifluoroacetate 作用下， 以 水 、 乙腈 为溶剂， 以83 %的产率得到3-甲基苯基丙酮
  参考文献：
  名称：

  通过顺序光生物催化方法从重氮盐到光学活性 1-Arylpropan-2-ols

  摘要：

  已经深入研究了在水性介质中蓝色 LED 光照射下芳香重氮盐和乙酸异丙烯酯之间的光催化 Meerwein 芳基化。在底物浓度、酯当量、共溶剂类型和用量、反应时间和光催化剂来源方面优化反应条件，允许使用 9-mesityl 获得各种 1-arylpropan-2-ones，产率高达 95% -10-甲基吖啶高氯酸盐 ([Acr-Mes]ClO 4). 接下来，通过将 Meerwein 芳基化与相应酮中间体的生物还原相结合，完成了单锅顺序光生物催化线性方法的设计。因此，根据醇脱氢酶的立体偏好，总共获得了 19 对 1-arylpropan-2-ol 对映异构体。全球收率高达 76%，立体选择性高至极佳（90 至 >99% ee）。此外，通过一锅三步顺序光生物催化方案，可以从苯胺开始获得两种 1-苯基丙-2-醇对映体（51-53% 产率）。

  DOI：

  10.1002/adsc.202300245

文献信息

• [EN] BCR-ABL TYROSINE-KINASE LIGANDS CAPABLE OF DIMERIZING IN AN AQUEOUS SOLUTION, AND METHODS OF USING SAME<br/>[FR] LIGANDS DE TYROSINE-KINASE BCR-ABL CAPABLES DE SE DIMÉRISER DANS UNE SOLUTION AQUEUSE, ET PROCÉDÉS D'UTILISATION DE CEUX-CI
  申请人：COFERON INC

  公开号：WO2015106292A1

  公开（公告）日：2015-07-16

  Described herein are monomers capable of forming a biologically useful multimer when in contact with one, two, three or more other monomers in an aqueous media. In one aspect, such monomers may be capable of binding to another monomer in an aqueous media (e.g. invivo) to form a multimer (e.g. a dimer). Contemplated monomers may include a ligand moiety, a linker element, and a connector element that joins the ligand moiety and the linker element. In an aqueous media, such contemplated monomers may join together via each linker element and may thus be capable of modulating one or more biomolecules substantially simultaneously, e.g., modulate two or more binding sites on a Bcr-Abl tyrosine kinase.

  本文描述了一种单体，当与水性介质中的另一个、两个、三个或更多其他单体接触时，能够形成生物学上有用的多聚体。在一个方面，这种单体可能能够在水性介质（例如体内）中与另一个单体结合以形成多聚体（例如二聚体）。考虑到的单体可能包括配体基团、连接元素和连接配体基团与连接元素的连接元素。在水性介质中，这些考虑到的单体可以通过每个连接元素结合在一起，因此可以同时调节一个或多个生物分子，例如，调节Bcr-Abl酪氨酸激酶上的两个或更多结合位点。
• [EN] NAPTHALENE ACETIC ACID DERIVATIVES AGAINST HIV INFECTION<br/>[FR] DÉRIVÉS D'ACIDE NAPHTALÈNE ACÉTIQUE CONTRE L'INFECTION PAR LE VIH
  申请人：GILEAD SCIENCES INC

  公开号：WO2013103738A1

  公开（公告）日：2013-07-11

  The invention provides compounds and salts thereof as d herein. The invention also provides pharmaceutical compositions comprising a compound disclosed herein, processes for preparing compounds disclosed herein, intermediates useful for preparing compounds disclosed herein and therapeutic methods for treating an HIV infection, treating the proliferation of the HIV virus, treating AIDS or delaying the onset of AIDS or ARC symptoms in a mammal using compounds disclosed herein.

  该发明提供了作为d的化合物及其盐。该发明还提供了包括本文所披露的化合物的药物组合物，用于制备本文所披露的化合物的过程，用于制备本文所披露的化合物的中间体，以及使用本文所披露的化合物治疗HIV感染、治疗HIV病毒的增殖、治疗艾滋病或延缓哺乳动物发生艾滋病或ARC症状的治疗方法。
• 一种含哌啶噻唑类化合物在制备杀菌剂中的 应用及其制备方法
  申请人：浙江工业大学

  公开号：CN107646855B

  公开（公告）日：2020-07-07

  本发明公开了提供了一种含哌啶噻唑类化合物作为杀菌剂在防治黄瓜霜霉病和水稻纹枯病中的应用，以及含哌啶噻唑类化合物的制备方法。本发明提供了含哌啶噻唑类化合物的一种新的应用，该类化合物是具有杀菌活性的新化合物，为哌啶噻唑类农药研发提供了基础，本发明的制备方法为杀菌剂的制备提供了原料基础。
• Reaction Pathway and Rate-Determining Step of the Schmidt Rearrangement/Fragmentation: A Kinetic Study
  作者：Ryo Akimoto、Takehiro Tokugawa、Yutaro Yamamoto、Hiroshi Yamataka

  DOI：10.1021/jo300419c

  日期：2012.4.20

  pre-equilibrium in the formation of iminodiazonium (ID) ion and that the N2 liberation from the ID ion is rate-determining. Under high azide concentration conditions, where the effective reactant is the ID ion, the reaction gave a linear Hammett plot with a ρ value of −0.50. The observed substituent effects on the rate and the product selectivity imply that path bifurcation on the way from the rate-determining

  三甲基叠氮化硅在90％（v / v）的TFA水溶液中将3-苯基-2-丁酮与取代的3-苯基-2-丁酮进行Schmidt重排，生成了两种类型的产物：碎片和重排，其比例取决于取代基：碎片越多，电子越多-供体取代基。通过固氮法进行的速率测量表明存在诱导期，并且拟一级反应速率常数显示出相对于叠氮化物浓度的饱和动力学。结果表明，反应通过预平衡进行，形成亚氨基重氮（ID）离子，并且N 2从ID离子的释放是决定速率的。在高叠氮化物浓度的条件下，其中有效反应物是ID离子，该反应给出了ρ值为-0.50的线性Hammett图。如先前的分子动力学模拟所示，观察到的取代基对速率和产物选择性的影响暗示着从速率确定TS到产物态的路径发生分支，类似于贝克曼重排/片段化反应。
• [EN] PYRIMIDINE DERIVATIVES CAPABLE OF INHIBITING ONE OR MORE KINASES<br/>[FR] DÉRIVÉS DE PYRIMIDINE CAPABLES D'INHIBER UNE OU PLUSIEURS KINASES
  申请人：MEDICAL RES COUNCIL

  公开号：WO2009122180A1

  公开（公告）日：2009-10-08

  A first aspect of the invention relates to a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, formula (I): wherein: R1 is C3-8-cycloalkyl; X is O, NR7 or C3-6-heterocycloalkyl; R2 is aryl, heteroaryl, fused or unfused aryl-C3-6-heterocycloalkyl or fused or unfused heteroaryl-C3-6-heterocycIoalkyl, each of which is optionally substituted by one or more substitutents selected from aryl, heteroaryl, C1-6-alkyl, C3-7-cycloalkyl and a group A, wherein said C1-6-alkyl group is optionally substituted by one or more substituents selected from aryl, heteroaryl, R10 and a group A, said heteroaryl group is optionally substituted by one or more R10 groups; and wherein said C3-6-heterocycloalkyl group optionally contains one or more groups selected from oxygen, sulfur, nitrogen and CO; R3 is C1-6-alkyl optionally substituted by one or more substituents selected from aryl, heteroaryl, -NR4R5, -OR6, -NR7(CO)R6, -NR7(CO)NR4R5, -NR7SO2R6, -NR7COOR7, -CONR4R5, C3-6-heterocycloalkyl and formula (a, b, c): wherein R4-7 and A are as defined in the claims. Further aspects relate to the use of said compounds in the treatment of various therapeutic disorders, and more particularly as inhibitors of one or more kinases.

  本发明的第一个方面涉及式(I)的化合物，或其药学上可接受的盐或酯，式(I)如下：其中：R1为C3-8环烷基；X为O、NR7或C3-6杂环烷基；R2为芳基、杂芳基、融合或未融合的芳基-C3-6杂环烷基或融合或未融合的杂芳基-C3-6杂环烷基，每个基可选择地由来自芳基、杂芳基、C1-6烷基、C3-7环烷基和A基的一个或多个取代基取代，其中所述C1-6烷基基可选择地由来自芳基、杂芳基、R10和A基的一个或多个取代基取代，所述杂芳基可选择地由一个或多个R10基取代；以及所述C3-6杂环烷基基可选择地包含一个或多个来自氧、硫、氮和CO的基；R3为C1-6烷基，可选择地由一个或多个来自芳基、杂芳基、-NR4R5、-OR6、-NR7(CO)R6、-NR7(CO)NR4R5、-NR7SO2R6、-NR7COOR7、-CONR4R5、C3-6杂环烷基和式(a, b, c)的取代基取代；其中R4-7和A如权利要求中所定义。进一步方面涉及所述化合物在治疗各种治疗性疾病中的使用，特别是作为一个或多个激酶的抑制剂。